Rabies virus (Pasteur vaccins/PV) Pseudotyped Virus (GFP-Luciferase)

Rabies virus (RABV) binds to cell receptors via its G protein, inducing the production of neutralizing antibodies. To avoid the biosafety risks associated with traditional RABV neutralization assays that involve live virus, a pseudovirus has been developed based on the HIV lentiviral backbone, with rabies virus G protein (RABV-G; NCBI Reference Sequence: NC_001542.1) embedded on its surface. This pseudovirus simulates the process of the live virus binding to receptors and entering the receptor cells. Additionally, the pseudovirus carries GFP fluorescence and Luciferase reporter genes, allowing the evaluation of cell infection activity through fluorescence observation or luciferase activity detection. It can also be used to assess the ability of neutralizing antibodies to block pseudovirus infection of cells. The pseudovirus lacks self-replicating ability, ensuring high safety. It serves as an important tool for RABV-G receptor drug screening, neutralizing antibody activity detection, and vaccine efficacy evaluation.

Please contact us at for specific academic pricing.